BiomX Inc.
BiomX Inc.
- Market cap
- $1.88M
Your view on PHGE
Overview
What the company does, where it operates, and who runs it.
About BiomX Inc.
- Industry
- Aerospace & Defense
- Sector
- Industrials
- CEO
- Jonathan Eitan Solomon MBA
- Headquarters
- 22 Einstein Street, Ness Ziona, IL
- Industry
- Aerospace & Defense
- Sector
- Industrials
- CEO
- Jonathan Eitan Solomon MBA
- Headquarters
- 22 Einstein Street, Ness Ziona, IL
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria.
It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).
It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S.
aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients.
In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for BiomX Inc.. Starting points for BiomX Inc.: EPS -$44.04, beta 1.34 — an Aerospace & Defense name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for BiomX Inc.. Trailing twelve-month EPS for BiomX Inc. stands at -$44.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$38.00
average of analysts' targets
Analyst Ratings
- Strong Buy0
- Buy4
- Hold1
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrSep 2026 | Next QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | −$703.00 | −$655.50 | −$58.50 | −$60.10 |
| Low estimate | −$703.00 | −$655.50 | −$58.50 | −$60.10 |
| High estimate | −$703.00 | −$655.50 | −$58.50 | −$60.10 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | — | — | −$221.90 | — |
| Growth | — | — | +73.6% | — |
Revenue Estimate
| Revenue | Current QtrSep 2026 | Next QtrDec 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $332000.00 | $332000.00 | $23.55M | $57.46M |
| Low estimate | $332000.00 | $332000.00 | $23.55M | $57.46M |
| High estimate | $332000.00 | $332000.00 | $23.55M | $57.46M |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago revenue | — | — | $0.00 | — |
| Growth | — | — | — | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 20, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for BiomX Inc.. BiomX Inc. has reported as a listed company since 2019. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| BRTXBioRestorative Therapies, Inc. | Healthcare | Biotechnology | $1.8M | ||
| DWTXDogwood Therapeutics, Inc. | Healthcare | Biotechnology | $41.3M | ||
| EDSAEdesa Biotech, Inc. | Healthcare | Biotechnology | $19.8M | ||
| ERNAErnexa Therapeutics Inc. | Healthcare | Biotechnology | $2.7M | ||
| IMRNImmuron Limited | Healthcare | Biotechnology | $5.6M | ||
| MPLTMapLight Therapeutics, Inc. | Healthcare | Biotechnology | $283.4M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| THLLYThales S.A. | Industrials | OTC | $61.4B | ||
| TIKKTel-Instrument Electronics Corp. | Industrials | OTC | $8.3M | ||
| TURATurbine Aviation, Inc. | Industrials | OTC | $1 | ||
| TXTTextron Inc. | Industrials | NYSE | $14.0B | ||
| UITAUtilicraft Aerospace Industries, Inc. | Industrials | OTC | $75,679 | ||
| UMAVUAV Corp. | Industrials | OTC | $15 | ||
| VOYGVoyager Technologies, Inc. | Industrials | NYSE | $1.3B | ||
| VSECVSE Corporation | Industrials | NASDAQ | $5.2B | ||
| VSECUVSE Corporation | Industrials | NASDAQ | $1.1B | ||
| VVXV2X, Inc. | Industrials | NYSE | $2.5B | ||
| VWAVVisionWave Holdings, Inc. | Industrials | NASDAQ | $2.5M | ||
| VWAVWVisionWave Holdings, Inc. Warrant | Industrials | NASDAQ | $660,664 | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold BiomX Inc., and how their positions are changing. At a $1.9M market value, institutional positions materially move BiomX Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by BiomX Inc. executives and directors. Shares of BiomX Inc. have traded between $0.28 and $1.16 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for BiomX Inc.. Coverage tracks BiomX Inc. within Aerospace & Defense (Industrials). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of BiomX Inc.